Klotz Karl-Norbert, Kachler Sonja, Lambertucci Catia, Vittori Sauro, Volpini Rosaria, Cristalli Gloria
Institut für Pharmakologie und Toxikologie, Universität Würzburg, Versbacher Strasse 9, 97078 Würzburg, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):629-34. doi: 10.1007/s00210-003-0749-9. Epub 2003 May 7.
9-Ethyladenine was used as the basis for a series of non-xanthine adenosine receptor antagonists at human adenosine receptors. The adenine-based compounds were substituted in 2- or 8-position with a variety of side chains including some aryl or arylalkynyl groups previously tested as 2-substituents in adenosine and 5'-N-ethylcarboxamidoadenosine (NECA) for their effect on agonist affinity. The affinity of the novel compounds was tested in radioligand binding assays (A1, A2A and A3) and inhibition of NECA-stimulated adenylyl cyclase activity (A2B) in membranes prepared from CHO cells stably transfected with the respective human receptor subtype. High affinity antagonists were identified for A1 (9-ethyl-8-phenyl-9H-adenine, compound 2; 6-(1-butylamino)-9-ethyl-8-phenyl-9H-purine, compound 3), A2A (8-ethoxy-9-ethyladenine; compound 8) and A3 (9-ethyl-8-phenylethynyl-9H-adenine, compound 5) with selectivities versus other receptor subtypes in the range of 10 to 600. These results demonstrate that adenine is a useful template for further development of high-affinity antagonists with distinct receptor selectivity profiles.
9-乙基腺嘌呤被用作一系列人腺苷受体非黄嘌呤腺苷受体拮抗剂的基础。基于腺嘌呤的化合物在2-或8-位被各种侧链取代,包括一些先前作为腺苷和5'-N-乙基羧酰胺腺苷(NECA)中的2-取代基进行测试的芳基或芳基炔基,以研究其对激动剂亲和力的影响。在放射性配体结合试验(A1、A2A和A3)中测试了新型化合物的亲和力,并在稳定转染了相应人类受体亚型的CHO细胞膜中检测了其对NECA刺激的腺苷酸环化酶活性(A2B)的抑制作用。鉴定出了对A1(9-乙基-8-苯基-9H-腺嘌呤,化合物2;6-(1-丁基氨基)-9-乙基-8-苯基-9H-嘌呤,化合物3)、A2A(8-乙氧基-9-乙基腺嘌呤;化合物8)和A3(9-乙基-8-苯乙炔基-9H-腺嘌呤,化合物5)具有高亲和力的拮抗剂,其对其他受体亚型的选择性在10至600之间。这些结果表明,腺嘌呤是进一步开发具有独特受体选择性谱的高亲和力拮抗剂的有用模板。